RiconPharma is an R & D Company founded in April 2008, which is equipped with about 10,000 sq.ft., state of the art R & D facility located in Denville Technical Park, Denville, NJ, USA. RiconPharma develops novel drug delivery systems, alternate routes of administration, product enhancement, modified release dosage forms etc., for new products and support the life cycle management of approved pharmaceutical products.

RiconPharma's key focus areas are Pre-formulations, Formulation Development, Manufacturing Process Technologies, Analytical Testing, and Regulatory Submissions.

Pre-formulation studies emphasize Polymorphic Screening and Stabilization, Salt Screening, Solid State and Materials Characterization, Excipient Compatibility, Stability studies using HPLC, TGA, DSC, DVS (absorption/desorption), XRPD, Diffusion, and Particle Size analyzer.

Formulation Development emphasizes development of generics and new products (reduced strength, reduced frequency, combinations, and alternate routes of administration for approved products or unapproved grandfathered products under consideration of NDA 505 (b)(2) submissions).

Technology Development emphasize development of Platform Technologies such as Modified Release, Abuse Deterrent, ODT, Targeted Release, Follicular Delivery Systems, Drug Delivery Systems, Semi and Continuous Processing using Automation and Advanced PAT Controls.

Our core competencies are Oral Solids (IR, MR, ODT and Films), Topicals (Ointments, Creams, Lotions, Foams, and Gels), Transdermals (Matrix and Reservoir Systems), Liquids (Solutions and Suspensions) and Parenterals (Lyophilization).